NCT00435214|Completed
Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer
The HPV Persistence and Progression (PaP) Cohort at Kaiser Permanente Northern California
Loading search results
The HPV Persistence and Progression (PaP) Cohort at Kaiser Permanente Northern California
Sponsor study identifier
Secondary identifiers
observational
131,110
1 country
1
Study Start
January 29, 2007
Actual (reported)Primary Completion
April 1, 2020
Actual (reported)Study Completion
April 30, 2020
Actual (reported)Background:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 30, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 29, 2007
Actual (reported)February 13, 2007
Actual (reported)February 14, 2007
Actual (reported)April 1, 2020
Actual (reported)April 30, 2020
Actual (reported)CIN2+/CIN3+/Cancer
Cervical histopathology; The detection of CIN2+,CIN3+, or cancer in histology results from tissue collected during cervical biopsies, excisional treatment or surgery.
Ongoing
HPV Clearance
Ongoing
We are teaming with Kaiser Permanente Northern California (KPNC) to create a carcinogenic HPV-positive cohort (HPV Persistence and Progression Cohort or PaP Cohort) for investigating the natural history of HPV genotypes. Specifically, we will store approximately 60,000 baseline specimens from the following sub-populations: 1) approximately 40,000 HPV positives and a random population sample of 4,000 baseline specimens from women aged 30 years and older; 2) approximately 5,000 HPV-or-cytologypositives and random population sample of 2,000 baseline specimens from women aged 25-29 years of age; and 3) approximately 5,000 HPV-or cytology-positives and random population sample of 2,000 baseline specimens from women aged 21-24 years of age.
Kaiser Permanente Northern California
Oakland, California, 94612, United States
Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, Kinney W, Fetterman B, Lorey T, Schiffman M, Castle PE; PaP Cohort Study Group. Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol. 2012 Jan;50(1):61-5. doi: 10.1128/JCM.05989-11. Epub 2011 Nov 9.
Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, Shaber R, LaMere B, Clarke M, Lorincz AT, Castle PE, Schiffman M, Burk RD. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst. 2012 Nov 21;104(22):1738-49. doi: 10.1093/jnci/djs425. Epub 2012 Oct 23.
Discarded cervical Pap test specimens
Mark H Schiffman, M.D.
National Cancer Institute (NCI)
131,110 participants (actual enrollment reported by the registry).
First Submitted
February 13, 2007
First Posted
February 14, 2007
Study Start
January 29, 2007
Actual (reported)Evaluating Thermal Ablation in the Treatment of Cervical Neoplasia
Contact the study team to confirm eligibility.
Lamere BJ, Castle PE, Fetterman B, Poitras N, Stanley M, Shieh J, Lorey T, Kinney W, Schiffman M. A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: evidence against retesting. J Virol Methods. 2013 Apr;189(1):77-9. doi: 10.1016/j.jviromet.2013.01.011. Epub 2013 Feb 4. No abstract available.
Primary Completion
April 1, 2020
Actual (reported)Study Completion
April 30, 2020
Actual (reported)Last Updated
May 1, 2020
Record last verified: 2020-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: